BIOCRYST PHARMACEUTICALS INC's ticker is BCRX and the CUSIP is 09058V103. A total of 234 filers reported holding BIOCRYST PHARMACEUTICALS INC in Q3 2023. The put-call ratio across all filers is 0.15 and the average weighting 0.2%.
Quarter-by-quarter ownership
| Value | Shares | Weighting | ||||
|---|---|---|---|---|---|---|
| Q3 2023 | $20,909,881 | +0.7% | 2,953,373 | +0.1% | 0.00% | 0.0% |
| Q2 2023 | $20,766,578 | -60.7% | 2,949,798 | -53.4% | 0.00% | 0.0% |
| Q1 2023 | $52,834,066 | -35.4% | 6,335,020 | -11.0% | 0.00% | -75.0% |
| Q4 2022 | $81,749,023 | +13.7% | 7,120,995 | +24.8% | 0.01% | +14.3% |
| Q3 2022 | $71,910,000 | +31.0% | 5,707,067 | +10.0% | 0.01% | +40.0% |
| Q2 2022 | $54,887,000 | -59.9% | 5,187,777 | -38.3% | 0.01% | -54.5% |
| Q1 2022 | $136,819,000 | +153.5% | 8,414,458 | +116.0% | 0.01% | +175.0% |
| Q4 2021 | $53,963,000 | +234.1% | 3,896,248 | +246.6% | 0.00% | +300.0% |
| Q3 2021 | $16,154,000 | -9.1% | 1,124,179 | -0.0% | 0.00% | 0.0% |
| Q2 2021 | $17,776,000 | +116.8% | 1,124,333 | +39.4% | 0.00% | 0.0% |
| Q1 2021 | $8,201,000 | +36.5% | 806,386 | +0.0% | 0.00% | 0.0% |
| Q4 2020 | $6,007,000 | +25.1% | 806,284 | -42.3% | 0.00% | – |
| Q3 2020 | $4,802,000 | -60.6% | 1,398,084 | -45.3% | 0.00% | -100.0% |
| Q2 2020 | $12,182,000 | +138.3% | 2,556,584 | 0.0% | 0.00% | 0.0% |
| Q1 2020 | $5,113,000 | +15.2% | 2,556,584 | +98.7% | 0.00% | – |
| Q4 2019 | $4,439,000 | -13.4% | 1,286,541 | -28.1% | 0.00% | -100.0% |
| Q3 2019 | $5,124,000 | -53.3% | 1,788,541 | -38.2% | 0.00% | 0.0% |
| Q2 2019 | $10,971,000 | -61.1% | 2,894,741 | -16.5% | 0.00% | -66.7% |
| Q1 2019 | $28,229,000 | +16.9% | 3,467,998 | +15.9% | 0.00% | 0.0% |
| Q4 2018 | $24,146,000 | -15.7% | 2,992,009 | -20.3% | 0.00% | 0.0% |
| Q3 2018 | $28,641,000 | +13.1% | 3,753,803 | -15.0% | 0.00% | 0.0% |
| Q2 2018 | $25,319,000 | +20.1% | 4,418,631 | 0.0% | 0.00% | 0.0% |
| Q1 2018 | $21,077,000 | +37.4% | 4,418,631 | +41.4% | 0.00% | +50.0% |
| Q4 2017 | $15,342,000 | -6.3% | 3,124,676 | 0.0% | 0.00% | 0.0% |
| Q3 2017 | $16,373,000 | -5.8% | 3,124,676 | 0.0% | 0.00% | 0.0% |
| Q2 2017 | $17,373,000 | +42.0% | 3,124,676 | +114.5% | 0.00% | 0.0% |
| Q1 2017 | $12,238,000 | +162.1% | 1,456,885 | +97.5% | 0.00% | +100.0% |
| Q4 2016 | $4,670,000 | +342.2% | 737,723 | +207.9% | 0.00% | – |
| Q3 2016 | $1,056,000 | +105.4% | 239,562 | +32.3% | 0.00% | – |
| Q2 2016 | $514,000 | -81.8% | 181,100 | -81.9% | 0.00% | – |
| Q1 2016 | $2,830,000 | -96.3% | 1,000,000 | -86.6% | 0.00% | -100.0% |
| Q4 2015 | $77,277,000 | -12.5% | 7,488,027 | -3.4% | 0.01% | -23.1% |
| Q3 2015 | $88,351,000 | -38.6% | 7,750,127 | -19.6% | 0.01% | -27.8% |
| Q2 2015 | $143,999,000 | +47.0% | 9,644,931 | -11.1% | 0.02% | +50.0% |
| Q1 2015 | $97,958,000 | -22.7% | 10,848,020 | +4.1% | 0.01% | -25.0% |
| Q4 2014 | $126,761,000 | +21.7% | 10,424,425 | -2.1% | 0.02% | +14.3% |
| Q3 2014 | $104,121,000 | -23.9% | 10,646,325 | -0.8% | 0.01% | -22.2% |
| Q2 2014 | $136,887,000 | +43.9% | 10,736,225 | +19.4% | 0.02% | +38.5% |
| Q1 2014 | $95,139,000 | +380.8% | 8,992,381 | +245.4% | 0.01% | +333.3% |
| Q4 2013 | $19,788,000 | +9794.0% | 2,603,700 | +9368.0% | 0.00% | – |
| Q3 2013 | $200,000 | – | 27,500 | – | 0.00% | – |
Download | ||||||
Other shareholders
| Name | Shares | Value | Weighting ↓ |
|---|---|---|---|
| Burrage Capital Management LLC | 864,916 | $13,674,000 | 13.71% |
| Sarissa Capital Management LP | 4,261,000 | $67,366,000 | 5.36% |
| ORACLE INVESTMENT MANAGEMENT INC | 1,920,733 | $30,367,000 | 4.18% |
| HealthCor Management, L.P. | 3,248,100 | $51,352,000 | 2.05% |
| Parkman Healthcare Partners LLC | 351,961 | $5,565,000 | 1.22% |
| Bain Capital Public Equity Management II, LLC | 1,560,730 | $24,675,000 | 1.06% |
| Baker Brothers Advisors | 12,710,818 | $200,958,000 | 0.88% |
| DEERFIELD MANAGEMENT COMPANY, L.P. (SERIES C) | 2,835,000 | $44,821,000 | 0.80% |
| Biondo Investment Advisors, LLC | 265,840 | $4,203,000 | 0.72% |
| EAM Global Investors LLC | 157,065 | $2,483,000 | 0.69% |